

Sorafenib Tosylate

产品名称	Sorafenib Tosylate
公司名称	上海皓元生物医药科技有限公司
价格	.00/个
规格参数	品牌:MCE
公司地址	上海市浦东新区张衡路1999弄3号楼
联系电话	021-58955995 18317190548

产品详情

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Sorafenib Tosylate

CAS No. : [475207-59-1](#)

MCE 国际站 : [Sorafenib Tosylate](#)

产品活性：Sorafenib Tosylate (Bay 43-9006 Tosylate) 是一种有效的口服活性 Raf 抑制剂，对 Raf-1 和 B-Raf 的 IC50 分别为 6 nM 和 20 nM。Sorafenib Tosylate 是一种多激酶抑制剂，对 VEGFR2，VEGFR3，PDGFR，FLT3 和 c-Kit 的 IC50 分别为 90 nM，15 nM，20 nM，57 nM 和 58 nM。Sorafenib Tosylate 诱导细胞自噬 (autophagy) 和凋亡 (apoptosis)，并具有抗肿瘤活性。Sorafenib Tosylate 也是一种 ferroptosis 激动剂。

研究领域：[MAPK/ERK Pathway](#) | [Protein Tyrosine Kinase/RTK](#) | [Autophagy](#)
| [Apoptosis](#)

作用靶点：[Raf](#) | [VEGFR](#) | [FLT3](#) | [Autophagy](#) | [Ferroptosis](#)
| [Apoptosis](#)

In Vitro: Sorafenib Tosylate also inhibits BRAFwt (IC₅₀=22 nM), BRAFV599E (IC₅₀=38 nM), VEGFR-2 (IC₅₀=90 nM), VEGFR-3 (IC₅₀=20 nM), PDGFR- (IC₅₀=57 nM), c-KIT (IC₅₀=68 nM), and Flt3 (IC₅₀=58 nM) in biochemical assays. Sorafenib-induced phosphorylation of c-Met, p70S6K and 4EBP1 is significantly reduced when 10-0505 cells are co-treated with anti-human anti-HGF antibody, suggesting that treatment with Sorafenib Tosylate leads to increased HGF secretion and activation of c-Met and mTOR targets.

In Vivo: Sorafenib Tosylate (10, 30, 50 and 100 mg/kg, orally) treatment inhibits the tumor growth of 06-0606 and 10-0505 xenografts in a dose-dependent manner (P<0.01). The growth rate of 06-0606 and 10-0505 xenografts is also significantly reduced by Sorafenib. The weights of 06-0606 tumors in mice that are treated with Sorafenib 50 mg/kg and 100 mg/kg are approximately 13% and 5% of the controls, respectively. 50 mg dose of Sorafenib significantly inhibits tumor growth in mice with lines 5-1318, 26-1004 and 10-0505 (P<0.01). For 50 mg dose, the T/C ratio, where T and C are the median weight (mg) of Sorafenib- and vehicle-treated tumors at the end of the treatment, respectively, for 06-0606, 26-1004, 5-1318, and 10-0505 xenografts is 0.13, 0.10, 0.12 and 0.49, respectively. The survival rate is 73.3 % in Diethyl nitrosamine (DENA) group and 83.3 % in Sorafenib group compared to 100 % in the normal control group. DENA group shows a significant increase in liver index (1.51-fold increase, p<0.05) compared to normal control group, while treatment with Sorafenib shows significant decrease (p<0.05) in liver index when compared to DENA group. The liver index in Sorafenib group significantly decreases to lower than its value in the normal control.

相关产品 : [Covalent Screening Library Plus](#) | [Drug Repurposing Compound Library Plus](#)
| [FDA-Approved Drug Library Plus](#) | [FDA-Approved Drug Library Mini](#)
| [Bioactive Compound Library Plus](#) | [Apoptosis Compound Library](#)
| [Immunology/Inflammation Compound Library](#) | [Kinase Inhibitor Library](#)
| [MAPK Compound Library](#) | [Protein Tyrosine Kinase Compound Library](#)
| [FDA-Approved Drug Library](#) | [Anti-Cancer Compound Library](#) | [CNS-
Penetrant Compound Library](#) | [Autophagy Compound Library](#) | [Anti-Aging Compound
Library](#) | [Drug Repurposing Compound Library](#) | [Covalent Screening Library](#)
| [Differentiation Inducing Compound Library](#) | [Reprogramming Compound Library](#)
| [Oxygen Sensing Compound Library](#) | [Ferroptosis Compound Library](#)
| [Anti-COVID-19 Compound Library](#) | [Orally Active Compound Library](#)
| [Glutamine Metabolism Compound Library](#) | [FDA Approved & Pharmacopeial Drug
Library](#) | [Anti-Breast Cancer Compound Library](#) | [Anti-Lung Cancer Compound Library](#)

Drug-Induced Liver Injury (DILI) Compound Library	Anti-Pancreatic Cancer Compound Library
Anti-Blood Cancer Compound Library	Targeted Therapy Drug Library
MG-132	Erastin
Ferrostatin-1	Cisplatin
LY294002	Doxorubicin hydrochloride
Bafilomycin A1	Paclitaxel
Cycloheximide	Y-27632 dihydrochloride
RSL3	Acetylcysteine
Angiotensin II human	Deferoxamine mesylate
SP600125	
5-Fluorouracil	Staurosporine
Bortezomib	Tamoxifen
2-Deoxy-D-glucose	Gemcitabine
Necrostatin-1	Verteporfin
Decitabine	Actinomycin D
Temozolomide	BAY 11-7082
Etoposide	Mitomycin C

品牌介绍:• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；• 设有专业的实验中心和严格的质控、验证体系；• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；• 产品的生物活性多经各国客户实验验证；• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；• 与世界各大制药公司及知名科研机构建立了长期的合作。